1. Discuss the role of pharmacogenomics in the identification of opportunities to reduce chemotherapy related toxicities
  2. Provide examples of drug-gene interactions which allow translation of germline genomic findings into clinical oncologic practice


  1. Examine the role of tumor microenvironment adenosine in immune evasion.
  2. Improve understanding of the pre-clinical data for A2AAR antagonists currently in clinical trial.
  3. Integrate epidemiologic data into pre-clinical pathway evaluation for investigational drugs, using A2AAR-targeted compounds as a case example.
Session date: 
11/05/2018 - 12:00pm to 1:00pm CST
5841 South Maryland Avenue
MC2115 HemOncConference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Natalie M. Reizine, MD and Garth W. Strohbehn, MD, MPhil